The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as ...
Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...
The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...
Hosted on MSN1d
Think Beyond GLP-1: True Weight Loss Requires MoreGLP-1 medications have become popular for weight loss, and for good reason—they can help regulate appetite and support weight ...
A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback